Multiple agent therapy for sexual dysfunction

US7235625B2 · kind B2 · utility

Assignee

• Palatin Technologies, Inc. · US

Inventors

• Lisa Diamond · Princeton, US
• Dennis C. Earle · Yardley, US
• Annette Shadiack · Somerville, US
• Shubh D. Sharma · Cranbury, US
• Carl Spana · Babylon, US

Key dates

• Filing date: May 26, 2005
• Grant date: Jun 26, 2007
• Expiry date: May 26, 2025

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S436/811
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.